

# The growing acceptance of baroreflex activation therapy for the treatment of resistant hypertension in Europe

- In the Netherlands – Recent data and current usage
- In Germany – Conclusions from the National Consensus Conference
- In Italy – Outcome of the Health Technology Assessment from the Lombardia region

## ESH CONGRESS, MILAN, ITALY

Saturday, 17 June 2017 from 10:00 to 11:00

Yellow Hall 1

### CHAired BY



**Prof Grassi**  
Milan,  
Italy



**Prof Pathak**  
Toulouse,  
France

### PRESENTED BY



**Prof Kroon,**  
Maastricht,  
Netherlands



**Prof Reuter**  
Cologne,  
Germany



**Prof Agabiti Rosei**  
Brescia,  
Italy

BAROSTIM NEO™ is CE Marked and approved for sale for hypertension patients in Europe. It is also CE Marked and approved for sale for heart failure patients in Europe. For more information, please visit [www.barostimtherapy.com](http://www.barostimtherapy.com). CVRx, BAROSTIM NEO, Baroreflex Activation Therapy and BAROSTIM THERAPY are all trademarks of CVRx, Inc. © 2016 CVRx, Inc. All rights reserved.